kynurenine has been researched along with Cancer of Pancreas in 13 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, a new mathematical model was established and validated to forecast and define sensitive targets in the kynurenine pathway (Kynp) in pancreatic adenocarcinoma (PDAC)." | 8.02 | Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling. ( Alahdal, M; Duan, L; Ouyang, H; Sun, D; Wang, D; Wang, M; Xiong, J, 2021) |
| "Metabolomic profiling identified glucose and kynurenine to have potential clinical utility for differentiating mucinous from nonmucinous pancreatic cysts." | 7.79 | Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. ( Banerjee, S; Bowen, R; Chen, AM; Fitch, WL; Friedland, S; Lowe, AW; Norton, JA; Pai, RK; Park, WG; Pasricha, PJ; Peltz, G; Poultsides, GA; Scott, BA; Visser, BC; Wodziak, D; Wu, M; Zheng, M, 2013) |
| " Herein, we study the role of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme important in the conversion of tryptophan to kynurenine, in a murine model of pancreatic cancer-associated depression." | 4.12 | IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression. ( Graor, HJ; Hajihassani, O; Hue, JJ; Ji, K; Katayama, ES; Loftus, AW; Vaziri-Gohar, A; Winter, JM; Zarei, M, 2022) |
| "In this study, a new mathematical model was established and validated to forecast and define sensitive targets in the kynurenine pathway (Kynp) in pancreatic adenocarcinoma (PDAC)." | 4.02 | Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling. ( Alahdal, M; Duan, L; Ouyang, H; Sun, D; Wang, D; Wang, M; Xiong, J, 2021) |
| "17 patients with pancreatic adenocarcinoma were recruited and completed mood questionnaires (Functional Assessment of Cancer Therapy -Pancreatic Cancer, Beck Depression Inventory and the Beck Anxiety Inventory) and blood testing for serum levels of tryptophan, kynurenine, kynurenic acid and quinolinic acid." | 3.80 | A biological basis for depression in pancreatic cancer. ( Botwinick, IC; Chabot, JA; Cooper, T; Mann, JJ; Pursell, L; Yu, G, 2014) |
| "Metabolomic profiling identified glucose and kynurenine to have potential clinical utility for differentiating mucinous from nonmucinous pancreatic cysts." | 3.79 | Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. ( Banerjee, S; Bowen, R; Chen, AM; Fitch, WL; Friedland, S; Lowe, AW; Norton, JA; Pai, RK; Park, WG; Pasricha, PJ; Peltz, G; Poultsides, GA; Scott, BA; Visser, BC; Wodziak, D; Wu, M; Zheng, M, 2013) |
| "In the SUPPORT study, adult pancreatic cancer patients were randomized to intervention programs of 6-month (1) a Supervised moderate-to-high-intensity progressive resistance training or (2) unsupervised Home-based resistance training, or (3) to a standard care patient Control group." | 3.01 | Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients. ( Clauss, D; Pal, A; Schmidt, ME; Steindorf, K; Ulrich, CM; Wiskemann, J; Zimmer, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, H | 1 |
| Li, T | 1 |
| Fang, X | 1 |
| Xing, Z | 1 |
| Zhang, S | 1 |
| Shi, L | 1 |
| Li, W | 1 |
| Guo, L | 1 |
| Kuang, C | 1 |
| Liu, H | 1 |
| Yang, Q | 1 |
| Korac, K | 1 |
| Rajasekaran, D | 1 |
| Sniegowski, T | 1 |
| Schniers, BK | 1 |
| Ibrahim, AF | 1 |
| Bhutia, YD | 2 |
| Hue, JJ | 1 |
| Graor, HJ | 1 |
| Zarei, M | 1 |
| Katayama, ES | 1 |
| Ji, K | 1 |
| Hajihassani, O | 1 |
| Loftus, AW | 1 |
| Vaziri-Gohar, A | 1 |
| Winter, JM | 1 |
| Yang, T | 1 |
| Li, QQ | 1 |
| Liu, YM | 1 |
| Yang, B | 1 |
| Jonescheit, H | 1 |
| Oberg, HH | 1 |
| Gonnermann, D | 1 |
| Hermes, M | 1 |
| Sulaj, V | 1 |
| Peters, C | 1 |
| Kabelitz, D | 1 |
| Wesch, D | 1 |
| Pal, A | 1 |
| Zimmer, P | 1 |
| Clauss, D | 1 |
| Schmidt, ME | 1 |
| Ulrich, CM | 1 |
| Wiskemann, J | 1 |
| Steindorf, K | 1 |
| Alahdal, M | 1 |
| Sun, D | 1 |
| Duan, L | 1 |
| Ouyang, H | 1 |
| Wang, M | 1 |
| Xiong, J | 1 |
| Wang, D | 1 |
| Ogura, J | 1 |
| Miyauchi, S | 1 |
| Shimono, K | 1 |
| Yang, S | 1 |
| Gonchigar, S | 1 |
| Ganapathy, V | 1 |
| Huang, JY | 1 |
| Butler, LM | 1 |
| Midttun, Ø | 1 |
| Ulvik, A | 1 |
| Wang, R | 1 |
| Jin, A | 1 |
| Gao, YT | 1 |
| Ueland, PM | 1 |
| Koh, WP | 1 |
| Yuan, JM | 1 |
| Leja-Szpak, A | 1 |
| Góralska, M | 1 |
| Link-Lenczowski, P | 1 |
| Czech, U | 1 |
| Nawrot-Porąbka, K | 1 |
| Bonior, J | 1 |
| Jaworek, J | 1 |
| Park, WG | 1 |
| Wu, M | 1 |
| Bowen, R | 1 |
| Zheng, M | 1 |
| Fitch, WL | 1 |
| Pai, RK | 1 |
| Wodziak, D | 1 |
| Visser, BC | 1 |
| Poultsides, GA | 1 |
| Norton, JA | 1 |
| Banerjee, S | 1 |
| Chen, AM | 1 |
| Friedland, S | 1 |
| Scott, BA | 1 |
| Pasricha, PJ | 1 |
| Lowe, AW | 1 |
| Peltz, G | 1 |
| Botwinick, IC | 1 |
| Pursell, L | 1 |
| Yu, G | 1 |
| Cooper, T | 1 |
| Mann, JJ | 1 |
| Chabot, JA | 1 |
| Ehrhart, H | 1 |
| Ried, W | 1 |
| Benoit, W | 1 |
| Dörfler, H | 1 |
1 trial available for kynurenine and Cancer of Pancreas
| Article | Year |
|---|---|
Resistance Exercise Modulates Kynurenine Pathway in Pancreatic Cancer Patients.
Topics: Biomarkers; Disease Progression; Down-Regulation; Humans; Interleukin-6; Kynurenine; Metabolic Netwo | 2021 |
12 other studies available for kynurenine and Cancer of Pancreas
| Article | Year |
|---|---|
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Topics: Animals; Cell Movement; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Gene Expressi | 2021 |
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Topics: Animals; Cell Movement; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Gene Expressi | 2021 |
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Topics: Animals; Cell Movement; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Gene Expressi | 2021 |
IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Topics: Animals; Cell Movement; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Gene Expressi | 2021 |
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Topics: Animals; Carbidopa; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Kynurenine; Mice; Mice, Nud | 2022 |
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Topics: Animals; Carbidopa; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Kynurenine; Mice; Mice, Nud | 2022 |
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Topics: Animals; Carbidopa; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Kynurenine; Mice; Mice, Nud | 2022 |
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Topics: Animals; Carbidopa; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Kynurenine; Mice; Mice, Nud | 2022 |
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Topics: Animals; Depression; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; T | 2022 |
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Topics: Animals; Depression; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; T | 2022 |
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Topics: Animals; Depression; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; T | 2022 |
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Topics: Animals; Depression; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; T | 2022 |
T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; Th17 Cells; T | 2023 |
T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; Th17 Cells; T | 2023 |
T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; Th17 Cells; T | 2023 |
T cells in pancreatic cancer stroma: Tryptophan metabolism plays an important role in immunoregulation.
Topics: Animals; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice; Pancreatic Neoplasms; Th17 Cells; T | 2023 |
Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.
Topics: Adenocarcinoma; Adult; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Cycle Checkpoints; Cel | 2020 |
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling.
Topics: Adenocarcinoma; Cell Line, Tumor; Humans; Kynurenine; Models, Theoretical; Pancreatic Neoplasms; Rep | 2021 |
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling.
Topics: Adenocarcinoma; Cell Line, Tumor; Humans; Kynurenine; Models, Theoretical; Pancreatic Neoplasms; Rep | 2021 |
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling.
Topics: Adenocarcinoma; Cell Line, Tumor; Humans; Kynurenine; Models, Theoretical; Pancreatic Neoplasms; Rep | 2021 |
Forecasting sensitive targets of the kynurenine pathway in pancreatic adenocarcinoma using mathematical modeling.
Topics: Adenocarcinoma; Cell Line, Tumor; Humans; Kynurenine; Models, Theoretical; Pancreatic Neoplasms; Rep | 2021 |
Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy.
Topics: Active Transport, Cell Nucleus; Aryl Hydrocarbon Hydroxylases; Carbidopa; Cell Nucleus; Hep G2 Cells | 2017 |
A prospective evaluation of serum kynurenine metabolites and risk of pancreatic cancer.
Topics: 3-Hydroxyanthranilic Acid; Biomarkers; Case-Control Studies; China; Female; Humans; Kynurenine; Male | 2018 |
The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Topics: Antineoplastic Agents; Apoptosis; Azo Compounds; Cell Proliferation; Cell Survival; Dose-Response Re | 2019 |
The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Topics: Antineoplastic Agents; Apoptosis; Azo Compounds; Cell Proliferation; Cell Survival; Dose-Response Re | 2019 |
The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Topics: Antineoplastic Agents; Apoptosis; Azo Compounds; Cell Proliferation; Cell Survival; Dose-Response Re | 2019 |
The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1).
Topics: Antineoplastic Agents; Apoptosis; Azo Compounds; Cell Proliferation; Cell Survival; Dose-Response Re | 2019 |
Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cohort Studies; Cys | 2013 |
A biological basis for depression in pancreatic cancer.
Topics: Adenocarcinoma; Affect; Aged; Aged, 80 and over; Depression; Female; Humans; Kynurenine; Lymphatic M | 2014 |
[Studies on experimental leukemias (VII). Adenocarcinomas, sarcomas and leukemias in mice following subcutaneous injections of 3-hydroxykynurenine].
Topics: Animals; Carcinogens; Carcinoma; Injections, Subcutaneous; Kynurenine; Leukemia, Experimental; Leuke | 1968 |